OR4X2 Inhibitors
OR4X2 inhibitors encompass a broad range of compounds that interfere with the signaling pathways and regulatory mechanisms specific to the OR4X2 receptor, a member of the G protein-coupled receptors (GPCRs) family. The inhibition of kinases such as PKC by Staurosporine and Go 6983 leads to reduced phosphorylation of OR4X2, which is a critical regulator of receptor desensitization and internalization. Similarly, GF 109203X, another PKC inhibitor, leads to decreased OR4X2 signaling by hindering the receptor's regulatory phosphorylation. Inhibition of the PI3K/Akt pathway by LY294002 and Wortmannin impedes the intracellular trafficking and surface expression of OR4X2, thereby curtailing its signaling capabilities. This indicates a targeted approach where the inhibitors act to reduce receptor availability and function at the plasma membrane.
The second paragraph focuses on inhibitors that impact signaling cascades and cytoskeletal dynamics associated with GPCR function. U73122, by inhibiting PLC, disrupts the production of second messengers essential for GPCR signaling, which could attenuate the activity of OR4X2. SB 203580 and PD 98059 target the MAPK/ERK pathway, a common downstream signaling route for GPCRs, and their inhibition can lead to decreased activity of OR4X2 through reduced phosphorylation of regulatory proteins.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, known to suppress a wide range of kinases including PKC, which is a kinase that can phosphorylate G protein-coupled receptors (GPCRs) like OR4X2, leading to their desensitization or internalization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/Akt pathway. Since the PI3K/Akt pathway is involved in GPCR internalization, inhibiting this pathway can result in a reduction of OR4X2 internalization and recycling to the cell membrane, thus decreasing its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that prevents the phosphorylation and activation of Akt. By doing so, it can impair the functional activity of OR4X2 by reducing receptor recycling and promoting its degradation. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Go 6983 is a selective PKC inhibitor that can prevent phosphorylation of substrates by PKC. As GPCRs like OR4X2 may undergo PKC-dependent desensitization, Go 6983 can inhibit OR4X2 activity by preventing this desensitization process. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
GF 109203X is a selective inhibitor of PKC isoforms. It can inhibit OR4X2 activity by blocking PKC-mediated phosphorylation, which is crucial for GPCR signaling and regulation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor. Since p38 MAPK can be involved in the phosphorylation and regulation of GPCRs, inhibiting this kinase can lead to a decrease in OR4X2 functional activity due to reduced receptor phosphorylation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a MEK inhibitor that indirectly decreases ERK phosphorylation. ERK is often involved in the phosphorylation of GPCR-related proteins, and its inhibition can decrease OR4X2 activity by preventing such phosphorylation events. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632 is a ROCK inhibitor that can modulate GPCR activity by influencing actin cytoskeleton dynamics. Since GPCR function can be affected by cytoskeletal changes, inhibiting ROCK may lead to decreased OR4X2 signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can affect the overall cell signaling environment. As mTOR is involved in the regulation of protein synthesis and degradation, inhibiting this pathway can indirectly decrease the functional activity of OR4X2 by affecting receptor turnover. | ||||||
Clozapine | 5786-21-0 | sc-200402 sc-200402A | 50 mg 500 mg | $68.00 $357.00 | 11 | |
Clozapine is an antagonist for multiple GPCRs and can also influence GPCR signaling pathways indirectly. By acting on related receptors and pathways, clozapine can decrease OR4X2 signaling through cross-regulatory mechanisms within GPCR networks. | ||||||